Diet and WB-EMS Effects in Obesity

Starting soon · Not applicable

Conditions studied: Obesity & Overweight, Metabolic Disorders, Electrotherapy

In brief

Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness. Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood. This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks. Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.

Key facts

Study ID

NCT07562724

Run by

Firat University

People needed

40

Starts

2026-09-01

Expected to finish

2027-06-20

Last updated by the study team

2026-05-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18 and 65 years
• Body mass index (BMI) ≥ 30 kg/m²
• Sedentary lifestyle (less than 2 hours of structured exercise per week)
• Willingness to participate and provide written informed consent

You may not qualify if…

• Presence of pacemaker or implantable cardioverter-defibrillator
• Known cardiovascular disease or severe chronic illness
• Pregnancy or breastfeeding
• Uncontrolled diabetes or severe metabolic disorders
• Active malignancy or cancer treatment
• Severe renal or hepatic failure
• Acute infection or inflammatory disease
• Orthopedic conditions limiting physical activity
• Use of medications affecting body composition or appetite (e.g., corticosteroids, weight-loss drugs)
• Regular resistance training within the last 3 months
• Substance abuse, including alcohol or drug dependency
• Psychiatric or cognitive conditions affecting adherence to the study protocol

Where it is running

• Dicle University — Diyarbakır, Turkey (Türkiye)
• Firat University — Elâzığ, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.